DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6qrg4v/europe_orphan) has announced the addition of the "Europe Orphan Drug Market Outlook 2018" report to their offering.
The concept of rare diseases and the idea that a special attention needs to be given to this sector has been taking shape in Europe since the 1990s. ever since then the political aspects and initiatives related to orphan medicinal products have been emerging at both the EU level and at the level of member states individually.
Many member states in the EU have led the way during the 1990s in the space of orphan medicinal products, the result of which took the shape of the first European legislative text concerning rare diseases called the Orphan Medicinal Product Regulation. This Regulation was adopted in 1999 and came into effect in 2000.
Europe is the second largest market for orphan drugs. In the European region, rare disease is considered to be a priority area and research in this field is given high importance by the EU Framework Programmes for Research and Technological Development (FP) ever since the early 1990s. Increasing the utilization of scarce resources and coordinating research efforts are the basic factors which have been responsible for success in the European rare diseases market. However, the absence of an exhaustive rare disease classification, standard terms of reference and a harmonized regulatory requirement, has always been a challenge in this region, which is currently impacting the global sharing of information, data and samples which would boost the research further.
The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.
Europe Orphan Drug Market Outlook 2018- research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market:
- Europe Orphan Drug Market Overview
- Orphan Drug Designation Criteria
- Market Specific Reimbursement Policy & Regulatory Framework
- Europe Orphan Drug Pipeline by Phase, Indication & Originator
- Marketed Orphan drug List by Indication & Brand Name
- Key Issue to be Addressed
- Competitive Landscape
- AOP Orphan
- Genzyme Corporation
- Novartis Pharmaceuticals
- Orphan Europe
- Teva Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/6qrg4v/europe_orphan
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.